Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CGIH20014, Dunne, EA2187, Cholangiocarcino, Pevonedistat, Carboplatin, Paclitaxel

Basic Study Information

Purpose:
This phase II trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help the study doctors find out how well pevonedistat shrinks bile duct cancer of the liver when given alone and when in combination with paclitaxel and carboplatin.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Richard Dunne

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Return to Search